Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
IgA nephropathy is getting a major treatment upgrade. Final 2-year data from multiple phase 3 trials — including TELIGAN (telitacicept), ORIGIN (atacicept), and VISIONARY (sibeprenlimab) — show these immune-targeting drugs significantly slow kidney function decline and reduce proteinuria vs. placebo. The results are paving the way for full FDA approvals and a new standard of care for this progressive kidney disease.
IgA nephropathy (IgAN), a progressive immune-mediated kidney disease, is seeing a wave of promising therapies backed by robust 2-year trial data. At ASN Kidney Week in Denver, final results from multiple phase 3 trials confirmed that drugs targeting B-cell signaling pathways — specifically BAFF and APRIL — can meaningfully slow kidney function decline and sustain proteinuria reduction.
Telitacicept (TELIGAN trial) showed a 5.1 mL/min/1.73 m² eGFR advantage over placebo at 2 years, with 44% of patients achieving proteinuria remission vs. just 8% on placebo, and no patients progressing to kidney failure. Atacicept (ORIGIN trial) delivered a nearly identical eGFR benefit (5.0 mL/min/1.73 m² per year difference) and a 76% lower risk of kidney disease progression. Sibeprenlimab (VISIONARY trial) achieved a 97% risk reduction in composite kidney endpoints vs. placebo.
By the Numbers:
Why it matters: IgAN has long lacked disease-modifying therapies. These results — several of which are being submitted for full FDA approval — signal a paradigm shift toward immune-targeted treatment that could prevent kidney failure in a meaningful portion of patients.
